285 related articles for article (PubMed ID: 24828667)
41. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Lopez-Chavez A; Thomas A; Rajan A; Raffeld M; Morrow B; Kelly R; Carter CA; Guha U; Killian K; Lau CC; Abdullaev Z; Xi L; Pack S; Meltzer PS; Corless CL; Sandler A; Beadling C; Warrick A; Liewehr DJ; Steinberg SM; Berman A; Doyle A; Szabo E; Wang Y; Giaccone G
J Clin Oncol; 2015 Mar; 33(9):1000-7. PubMed ID: 25667274
[TBL] [Abstract][Full Text] [Related]
42. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M
Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527
[TBL] [Abstract][Full Text] [Related]
43. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
[TBL] [Abstract][Full Text] [Related]
44. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
47. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
48. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
[TBL] [Abstract][Full Text] [Related]
49. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
[TBL] [Abstract][Full Text] [Related]
50. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Amann JM; Lee JW; Roder H; Brahmer J; Gonzalez A; Schiller JH; Carbone DP
J Thorac Oncol; 2010 Feb; 5(2):169-78. PubMed ID: 20035238
[TBL] [Abstract][Full Text] [Related]
51. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
[TBL] [Abstract][Full Text] [Related]
52. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Gazdar AF
Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
[TBL] [Abstract][Full Text] [Related]
53. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Yu HA; Arcila ME; Rekhtman N; Sima CS; Zakowski MF; Pao W; Kris MG; Miller VA; Ladanyi M; Riely GJ
Clin Cancer Res; 2013 Apr; 19(8):2240-7. PubMed ID: 23470965
[TBL] [Abstract][Full Text] [Related]
54. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
[TBL] [Abstract][Full Text] [Related]
55. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
56. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
57. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
58. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
59. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Endoh H; Yatabe Y; Kosaka T; Kuwano H; Mitsudomi T
J Thorac Oncol; 2006 Sep; 1(7):629-34. PubMed ID: 17409929
[TBL] [Abstract][Full Text] [Related]
60. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]